Male contraceptives have not received adequate attention from both human and veterinary focused researchers, which has led to a marked deficiency of effective male contraceptive agents, resulting in a heavy dependence on female contraceptives to prevent unwanted and unplanned pregnancies. This is clearly demonstrated by canine overpopulation, which has been a worldwide problem for decades. Current research is trending towards developing novel, safe and effective contraceptive alternatives- with an emphasis on reduced side effects and potential reversibility. This has caused the focus to shift towards nonhormonal and reversible contraceptives, rather than the traditional hormone altering contraceptive agents because of their wide range of side effects due to alteration of the endogenous hormonal balance. One of the novel contraceptives that is undergoing trials is Triptonide, which is a derivative from an herb historically used in ancient Chinese medicine. Clinical and fertility trials in laboratory animals showed promise as a reversible, nonhormonal contraceptive and safe for long-term usage. However, Triptonide has not yet been tested in dogs. In my project, we aimed to determine the efficacy of Triptonide as a male contraceptive in dogs. This was done by treating young, healthy, and fertile male dogs (Beagles) to Triptonide and monitoring blood and semen parameters to determine the efficacy and safety, while compared to a placebo group. Ideally, Triptonide as a novel male contraceptive should be reversible, effective at the therapeutic dose with minimal adverse side effects and easy to administer. Triptonide shows promise as a viable alternative to castration for canine population control, while being suitable for further research on drug formulation.